People living with immune-mediated diseases such as rheumatoid disorders, inflammatory bowel disease or skin conditions can be affected for the rest of their lives. For example, the chronic immune-mediated skin disease psoriasis affects at least 100 million people worldwide1, and approximately 0.2% of Europe’s population live with inflammatory bowel diseases2.
By offering an expanding range of biosimilars in Europe to treat autoimmune disorders, STADA aims to improve patient access to life-altering medicines.
